


NS-638

Cat. No.:	HY-101428		
CAS No.:	150493-34-8		
Molecular Formula:	C ₁₅ H ₁₁ ClF ₃ N ₃		
Molecular Weight:	325.72		
Target:	Calcium Channel		
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 34 mg/mL (104.38 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent		1 mg	5 mg	10 mg
	Concentration	Mass			
	1 mM		3.0701 mL	15.3506 mL	30.7012 mL
	5 mM		0.6140 mL	3.0701 mL	6.1402 mL
	10 mM		0.3070 mL	1.5351 mL	3.0701 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

NS-638 is a small nonpeptide molecule with Ca²⁺-channel blocking properties. K⁺-stimulated intracellular Ca²⁺-elevation is blocked with an IC₅₀ value of 3.4 μM.

IC₅₀ & Target

IC₅₀: 3.4 μM (K⁺-stimulated intracellular Ca²⁺-elevation) [1]

In Vitro

NS-638 dose dependently inhibits K⁺-stimulated [45 Ca²⁺]-uptake in chick cortical synaptosomes and 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA)-stimulated [³H]GABA-release from cultured cortical neurons with IC₅₀ values of 2.3 and 4.3 μM, respectively. K⁺-stimulated intracellular Ca²⁺-elevation in cultured cerebellar granule cells is equipotently blocked with an IC₅₀ value of 3.4 μM. At this concentration no effect on Ca²⁺-induced contractions in K⁺-depolarized guinea pig taenia coli is observed. NS-638 reversibly blocks N- and L-type Ca²⁺-channels in cultured chick dorsal root ganglion cells in the concentration range of 1-30 μM^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In the mouse middle cerebral artery occlusion model, NS-638 administered i.p. (50 mg kg⁻¹) at 1 h and 6 h post-ischemia,

and once a day for the next two days, results in a 48% reduction in total infarct volume. It does not show protection against ischemic neuronal damage in the gerbil model of bilateral carotid artery occlusion^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]

The effect of NS-638 on neuronal Ca²⁺-channels is evaluated using whole cell patch clamp techniques^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[1]

Mice: In the mouse middle cerebral artery occlusion model, NS-638 is administered i.p. (50 mg kg⁻¹) at 1 h and 6 h post-ischemia, and once a day for the next two days^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. M?ller A, et al. Pharmacological profile and anti-ischemic properties of the Ca(2+)-channel blocker NS-638. *Neurol Res.* 1995 Oct;17(5):353-60.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA